BRPI0209824B8 - método ex vivo ou in vitro para induzir cardiomiogênese - Google Patents
método ex vivo ou in vitro para induzir cardiomiogêneseInfo
- Publication number
- BRPI0209824B8 BRPI0209824B8 BRPI0209824A BRPI0209824B8 BR PI0209824 B8 BRPI0209824 B8 BR PI0209824B8 BR PI0209824 A BRPI0209824 A BR PI0209824A BR PI0209824 B8 BRPI0209824 B8 BR PI0209824B8
- Authority
- BR
- Brazil
- Prior art keywords
- vivo
- vitro method
- encodes
- administration
- nucleotide sequence
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Dispersion Chemistry (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
método para induzir formação neovascular e regeneração de tecido. a presente invenção refere-se a um método para induzir formação neovascular e regeneração de tecido em mamíferos. o método reivindicado é caracterizado pela administração de uma seqüência de nucleotídeos que codifica o sítio ativo do fator de crescimento endotelial (vegf) . o método induz mitose celular, miocardiogênese, arteriogênese, vasculogênese e linfangiogênese em tecidos de mamíferos. o método emprega um vetor de plasmídeo que codifica a seqüência de nucleotídeo. a administração e realizada por rota intramiocardial.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ARP010102313A AR027161A1 (es) | 2001-05-15 | 2001-05-15 | Metodo para inducir la proliferacion neovascular y regeneracion tisular |
| ARP01-01-02313 | 2001-05-15 | ||
| PCT/US2002/014508 WO2002091995A2 (en) | 2001-05-15 | 2002-05-13 | Method to induce neovascular formation and tissue regeneration |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR0209824A BR0209824A (pt) | 2004-10-19 |
| BRPI0209824B1 BRPI0209824B1 (pt) | 2020-11-10 |
| BRPI0209824B8 true BRPI0209824B8 (pt) | 2021-05-25 |
Family
ID=36129783
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0209824-5 BRPI0209824B8 (pt) | 2001-05-15 | 2002-05-13 | método ex vivo ou in vitro para induzir cardiomiogênese |
Country Status (9)
| Country | Link |
|---|---|
| US (6) | US7563777B2 (pt) |
| EP (2) | EP2308502A1 (pt) |
| AR (1) | AR027161A1 (pt) |
| AU (1) | AU2002259162A1 (pt) |
| BR (1) | BRPI0209824B8 (pt) |
| CA (1) | CA2447343A1 (pt) |
| ES (1) | ES2566344T3 (pt) |
| MX (1) | MXPA03010532A (pt) |
| WO (1) | WO2002091995A2 (pt) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2142206B1 (en) | 2007-03-30 | 2014-07-30 | The Cleveland Clinic Foundation | SDF-1 for use in the treatment of ischemic peripheral vascular disorders |
| US20100272679A1 (en) | 2007-12-14 | 2010-10-28 | Penn Marc S | Compositions and methods of promoting wound healing |
| CA2772610C (en) * | 2009-08-28 | 2018-01-23 | The Cleveland Clinic Foundation | Sdf-1 delivery for treating ischemic tissue |
| US20140065110A1 (en) | 2012-08-31 | 2014-03-06 | The Regents Of The University Of California | Genetically modified msc and therapeutic methods |
| US9663564B2 (en) | 2013-03-15 | 2017-05-30 | The Regents Of The University Of California | Vectors and methods to treat ischemia |
| US10405961B2 (en) | 2013-03-14 | 2019-09-10 | Cell and Molecular Tissue Engineering, LLC | Coated surgical mesh, and corresponding systems and methods |
| US10130288B2 (en) | 2013-03-14 | 2018-11-20 | Cell and Molecular Tissue Engineering, LLC | Coated sensors, and corresponding systems and methods |
| US20170100029A1 (en) * | 2015-10-13 | 2017-04-13 | The University Of North Carolina At Chapel Hill | Compositions and Methods for Analyzing Collateral Density |
| AU2019210204B2 (en) | 2018-01-18 | 2024-05-16 | EndoProtech, Inc. | Treating microvascular dysfunction |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5219739A (en) * | 1989-07-27 | 1993-06-15 | Scios Nova Inc. | DNA sequences encoding bVEGF120 and hVEGF121 and methods for the production of bovine and human vascular endothelial cell growth factors, bVEGF120 and hVEGF121 |
| US6040157A (en) * | 1994-03-08 | 2000-03-21 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 |
| WO1998032859A1 (en) * | 1997-01-29 | 1998-07-30 | Cornell Research Foundation, Inc. | Multiple site delivery of adenoviral vector for the induction of angiogenesis |
| JP2003517265A (ja) * | 1997-12-24 | 2003-05-27 | ルードヴィッヒ インスティテュート フォー キャンサー リサーチ | 血管内皮増殖因子ｄを発現する発現ベクターおよび細胞系、およびメラノーマを治療する方法 |
| US20010056073A1 (en) * | 1998-07-21 | 2001-12-27 | Ascher Shmulewitz | Gene therapy method for revascularizing ischemic tissue |
| US6440945B1 (en) * | 1999-05-27 | 2002-08-27 | Instituto Dermopatico Dell'immacolata | Method of inducing angiogenesis in nonis chemic skeletal muscle |
| CA2381780C (en) * | 1999-08-13 | 2015-03-10 | Chiron Corporation | Dose of an angiogenic factor and method of administering to improve myocardial blood flow |
-
2001
- 2001-05-15 AR ARP010102313A patent/AR027161A1/es not_active Application Discontinuation
-
2002
- 2002-05-13 EP EP10011850A patent/EP2308502A1/en not_active Withdrawn
- 2002-05-13 MX MXPA03010532A patent/MXPA03010532A/es active IP Right Grant
- 2002-05-13 ES ES02729151.7T patent/ES2566344T3/es not_active Expired - Lifetime
- 2002-05-13 WO PCT/US2002/014508 patent/WO2002091995A2/en not_active Application Discontinuation
- 2002-05-13 CA CA002447343A patent/CA2447343A1/en not_active Abandoned
- 2002-05-13 EP EP02729151.7A patent/EP1441682B1/en not_active Expired - Lifetime
- 2002-05-13 BR BRPI0209824-5 patent/BRPI0209824B8/pt not_active IP Right Cessation
- 2002-05-13 AU AU2002259162A patent/AU2002259162A1/en not_active Abandoned
-
2003
- 2003-11-17 US US10/714,449 patent/US7563777B2/en not_active Expired - Lifetime
-
2009
- 2009-06-18 US US12/487,398 patent/US20090275645A1/en not_active Abandoned
-
2014
- 2014-02-10 US US14/176,616 patent/US20140341972A1/en not_active Abandoned
-
2016
- 2016-06-06 US US15/173,867 patent/US20160346352A1/en not_active Abandoned
-
2017
- 2017-04-18 US US15/490,198 patent/US20170252405A1/en not_active Abandoned
-
2018
- 2018-04-05 US US15/945,982 patent/US20180296641A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AR027161A1 (es) | 2003-03-19 |
| US20050020522A1 (en) | 2005-01-27 |
| WO2002091995A2 (en) | 2002-11-21 |
| WO2002091995A8 (en) | 2004-05-06 |
| US20180296641A1 (en) | 2018-10-18 |
| US20160346352A1 (en) | 2016-12-01 |
| US20090275645A1 (en) | 2009-11-05 |
| EP2308502A1 (en) | 2011-04-13 |
| US20170252405A1 (en) | 2017-09-07 |
| BR0209824A (pt) | 2004-10-19 |
| BRPI0209824B1 (pt) | 2020-11-10 |
| MXPA03010532A (es) | 2005-10-05 |
| EP1441682A1 (en) | 2004-08-04 |
| ES2566344T3 (es) | 2016-04-12 |
| AU2002259162A1 (en) | 2002-11-25 |
| US20140341972A1 (en) | 2014-11-20 |
| EP1441682A4 (en) | 2007-07-11 |
| US7563777B2 (en) | 2009-07-21 |
| EP1441682B1 (en) | 2016-01-20 |
| CA2447343A1 (en) | 2002-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pacicca et al. | Expression of angiogenic factors during distraction osteogenesis | |
| ES2629086T3 (es) | Sustancia farmacéutica para promover la regeneración funcional de tejido dañado | |
| Oz et al. | Expression of aromatase in the human growth plate | |
| MX2022009460A (es) | Vacuna contra el coronavirus. | |
| Miyauchi et al. | Waon therapy upregulates Hsp90 and leads to angiogenesis through the Akt-endothelial nitric oxide synthase pathway in mouse hindlimb ischemia | |
| BR0214029A (pt) | Métodos e composições para o uso de células estromais para suportar células tronco embriÈnicas e adultas | |
| CY1113379T1 (el) | Πεπτιδια κdr και εμβολια που τα περιλαμβανουν | |
| BRPI0209824B8 (pt) | método ex vivo ou in vitro para induzir cardiomiogênese | |
| DE60039752D1 (de) | Herstellung tetravalenter antikörper | |
| BR0109494A (pt) | Produção de fatores recombinantes de coagulação do sangue em linhas celulares humanas | |
| DE69734605D1 (de) | Abgeschwächter salmonellenstamm, gebraucht als vehikel zur oralen immunisierung | |
| MX2023007574A (es) | "vacuna de arn contra variantes de sars-cov-2. | |
| MXPA04001334A (es) | Materiales y metodos para promover la reparacion de tejido nervioso. | |
| MXPA03006771A (es) | Anticuerpos modificados y metodos de uso. | |
| AR069830A1 (es) | Factor viii y factor de von willebrand recombinantes modificados y metodos de uso de los mismos | |
| CY1111386T1 (el) | Ενωσεις και μεθοδοι για αυξηση νευρογενεσης | |
| BR0011172A (pt) | Derivados do 4,5-diaril-3(2h)-furanona como inibidores de cliclooxigenase-2 | |
| DE60042828D1 (de) | Nicotinrezeptoragonisten in stammzellen und vorlaüferzellinduktion | |
| BRPI0514411A (pt) | formulação, e, método de produzir uma formulação | |
| CY1118073T1 (el) | Συνθεσεις και μεθοδοι για την αυξηση της δρασης της τελομερασης | |
| BR0211566A (pt) | Aparelho e método para redução de peso eletricamente condutor | |
| DE60137835D1 (de) | Modifizierte zytokine für krebs therapie | |
| Yamasaki et al. | Expression of heat shock proteins, Hsp70 and Hsp25, in the rat gingiva after irradiation with a CO2 laser in coagulation mode | |
| Yamagata et al. | Dietary apigenin regulates high glucose and hypoxic reoxygenation-induced reductions in apelin expression in human endothelial cells | |
| ATE415978T1 (de) | Sequentielle verabreichung von cpt-11 und apo-2l polypeptid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 9A ANUIDADE(S). |
|
| B08G | Application fees: restoration [chapter 8.7 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Free format text: AS CLASSIFICACOES ANTERIORES ERAM: A01N 43/04 , A01N 63/00 , C12P 21/06 , C12N 5/00 , C12N 15/00 , C12N 15/63 , C07H 21/02 , C07H 21/04 Ipc: A61K 48/00 (2006.01), C12N 15/63 (2006.01), A61P 7 |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/11/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/05/2002 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 21A ANUIDADE. |